<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="603">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630357</url>
  </required_header>
  <id_info>
    <org_study_id>N01037</org_study_id>
    <nct_id>NCT00630357</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Safety and Efficacy of Keppra After Conversion to Mono-therapy in Subjects With Partial Epilepsy</brief_title>
  <official_title>A Phase IV, Open-label, Multi-center Trial to Evaluate the Safety and Efficacy of KeppraÂ® After Conversion to Mono-therapy in Adult Subjects With Partial Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cohort of patients who became seizure-free during add-on treatment to one standard AED
      with Keppra in a previous trial (N01031) were followed to assess whether seizure freedom was
      maintained. Tolerability was documented.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigate seizure freedom with Keppra flexible dose.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam (Keppra)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of epilepsy with partial seizures;

          -  having completed the trial N01031 of Keppra as adjunctive therapy (SKATE);

          -  seizure-free over the last 3 months prior to protocol Visit 1;

          -  1 concomitant marketed AED at the time of trial entry and throughout the previous
             trial N01031;

          -  on the clinical judgment of the Investigator, progressive withdrawal of the
             concomitant AED and conversion to monotherapy with Keppra can be attempted.

        Exclusion Criteria:

          -  History of suicide attempt, current suicidal ideation, or other serious psychiatric
             disorders requiring or having required hospitalization or medication within the
             previous 5 years;

          -  presence of known pseudoseizures within the last year;

          -  presence or history of allergy to the components of Keppra (levetiracetam, lactose,
             cornstarch, and excipients) or other pyrrolidine derivatives;

          -  felbamate with less than 18 months exposure;

          -  vigabatrin, without visual field assessment as per recommendation of the
             manufacturer, i.e., every 6 months;

          -  uncountable seizures (clusters) or history of convulsive status epilepticus within
             the last 5 years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/N01037_CSS_20080108.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>February 27, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>UCB</organization>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Partial</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
